Urogen Pharma (NASDAQ:URGN) has earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have given a strong buy recommendation to the company.
Analysts have set a one year consensus price target of $28.00 for the company and are forecasting that the company will post ($0.05) earnings per share for the current quarter, according to Zacks. Zacks has also given Urogen Pharma an industry rank of 103 out of 265 based on the ratings given to related companies.
A number of research firms recently issued reports on URGN. Zacks Investment Research downgraded shares of Urogen Pharma from a “buy” rating to a “hold” rating in a report on Friday, August 18th. Oppenheimer Holdings, Inc. set a $32.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a report on Monday, August 14th. Raymond James Financial, Inc. began coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating and a $25.00 price objective on the stock. Jefferies Group LLC began coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Cowen and Company began coverage on shares of Urogen Pharma in a report on Tuesday, May 30th. They issued an “outperform” rating on the stock.
Large investors have recently modified their holdings of the business. Alps Advisors Inc. purchased a new position in Urogen Pharma during the second quarter valued at approximately $195,000. LLBH Private Wealth Management LLC purchased a new position in Urogen Pharma during the second quarter valued at approximately $695,000. Spark Investment Management LLC purchased a new position in Urogen Pharma during the second quarter valued at approximately $856,000. Menora Mivtachim Holdings LTD. purchased a new position in Urogen Pharma during the second quarter valued at approximately $2,331,000. Finally, Wildcat Capital Management LLC purchased a new position in Urogen Pharma during the second quarter valued at approximately $2,439,000. 36.06% of the stock is currently owned by institutional investors and hedge funds.
Shares of Urogen Pharma (NASDAQ:URGN) traded up 1.17% during trading on Tuesday, hitting $28.57. The stock had a trading volume of 3,175 shares. The firm’s market cap is $371.67 million. The stock has a 50-day moving average of $19.63 and a 200 day moving average of $18.25. Urogen Pharma has a 12-month low of $13.01 and a 12-month high of $29.89.
COPYRIGHT VIOLATION NOTICE: “Urogen Pharma (URGN) Given $28.00 Consensus Target Price by Analysts” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.themarketsdaily.com/2017/09/12/urogen-pharma-urgn-given-28-00-consensus-target-price-by-analysts.html.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.